171099-57-3

Basic information

• Product Name: ORITAVANCIN
• Synonyms: ORITAVANCIN;Oritavancin (LY333328);(4R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(p-chlorophenyl)benzyl)vancomycin;(4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]vancomycin;LY 333328;Orbactiv;Oritavancin (Lyophilized Powder For IV Infusion);(1S,2R,18R,19R,22S,25R,28R,40R)-22-(2-Amino-2-oxoethyl)-2-[(3-amino-2,3,6-trideoxy-3-methyl-α-L-arabino-hexopyranosyl)oxy]-5,15-dichloro-48-{[2-O-(3-{[(4'-chloro-4-biphenylyl)methyl]amino}-2,3,6-t
• CAS NO: 171099-57-3
• Molecular Formula: C86H97Cl3N10O26
• Molecular Weight: 1793.12
• Mol File: 171099-57-3.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.59±0.1 g/cm3(Predicted)
• PKA: 2.93±0.70(Predicted)
• CAS DataBase Reference: ORITAVANCIN(CAS DataBase Reference)
• NIST Chemistry Reference: ORITAVANCIN(171099-57-3)
• EPA Substance Registry System: ORITAVANCIN(171099-57-3)

Safety Data

• Hazardous Substances Data: 171099-57-3(Hazardous Substances Data)

Usage

Description

ORITAVANCIN is a semisynthetic glycopeptide antibiotic, which is utilized in the treatment of acute bacterial skin and skin structure infections. It is particularly effective against susceptible isolates of designated Gram-positive microorganisms, including Methicillin-resistant Staphylococcus aureus (MRSA). ORITAVANCIN functions by inhibiting bacterial cell wall synthesis, thereby preventing the growth and spread of the infection.

Uses

Used in Pharmaceutical Industry:
ORITAVANCIN is used as an antibiotic for the treatment of acute bacterial skin and skin structure infections. It is specifically effective against Gram-positive microorganisms, such as MRSA, due to its ability to inhibit bacterial cell wall synthesis and disrupt the growth and spread of the infection.
ORITAVANCIN is also used as a therapeutic agent for combating antibiotic-resistant bacterial strains, as it demonstrates potent activity against MRSA and other resistant Gram-positive bacteria. This makes it a valuable addition to the arsenal of antibiotics used in the fight against drug-resistant infections.

Clinical Use

Antibacterial agent

Enzyme inhibitor

This novel, semi-synthetic glycopeptide antibiotic (FW = 1793.10 g/mol; CAS 171099-57-3), also known as LY333328, Orbactiv?, and (4R)-22-O- (3-amino-2,3,6-trideoxy-3-C-methyl-a-L-arabinohexopyranosyl)-N3-(p-(pchlorophenyl) benzyl)vancomycin, disrupts the cell membrane of Grampositive bacteria and inhibits both transglycosylation and transpeptidation. Oritavancin differs from vancomycin by the presence of a hydrophobic N-4-(4-chlorophenyl)benzyl substituent on the disaccharide, the addition of a 4-epi-vancosamine monosaccharide to the amino acid residue in Ring-6, and replacement of the vancosamine moiety by 4-epi-vancosamine. When compared vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillinresistant methicillinresistant Staphylococcus aureus, LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Indeed, a single infusion of this antibiotic (1200 mg) can clear serious bacterial skin infections, including methicillin-resistant Staphylococcus aureus, or MRSA, as effectively as the usual 7-10 day, twice-daily regimen of vancomycin now needed to treat patients.

Drug interactions

Potentially hazardous interactions with other drugs Anticoagulants: possibly increases warfarin concentration.

Metabolism

In vitro human liver microsome studies indicated that oritavancin is not metabolised. It is excreted unchanged; less than 1% and 5% of a dose is recovered in the urine and the faeces.